ClinicalTrials.gg
CompletedNCT04355689SLO RPUpdated Jul 1, 2026

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

A Phase 1/2 interventional study of NPI-001 and Placebo in Usher Syndromes, sponsored by Nacuity Pharmaceuticals, Inc.. Completed at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Nacuity Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

Read the detailed description

This study will examine the safety and efficacy of oral NPI-001 Tablets as compared to oral placebo tablets for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

02

Conditions studied

  • Usher Syndromes

Browse trials for

Keywords

  • retinitis pigmentosa Usher vision NPI-001 tablet
03

In context

Usher Syndromes

33 studies on the registry are indexed under Usher Syndromes; 13 are open to participants now.

This study's enrollment of 49 is above the median of 39 across 18 interventional studies indexed under Usher Syndromes.

Browse Usher Syndromes studies →

Lead sponsor

Nacuity Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years.
  2. Able to comprehend and willing to sign an form (ICF) and to adhere to the study protocol.
  3. Diagnosed with Usher syndrome.
  4. EZ zone with width ≥500 microns, which includes the fovea in each eye at Visit 2, (Screen B).
  5. Have at least 20 detectable points on the MAIA grid.
  6. On stable dose of medications associated with other conditions for at least one month.
  7. Both female participants of and male participants able to father children must have (or have a partner who has) had a bilateral oophorectomy, hysterectomy or bilateral salpingectomy; must abstain from intercourse; or must agree to practice 2 acceptable methods of throughout the course of the study and 4 weeks after the last visit. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, tubal ligation, or vasectomy.

Exclusion criteria

Exclusion Criteria:

Ocular:

  1. All edges of the EZ area in both eyes cannot be visualized at Visit 2 (Screen B).
  2. Concurrent retinal pathologies that result in vision loss or inability to fixate, including but not limited to, choroideremia, retinal vein occlusion, and neovascular age-related macular degeneration.
  3. Intraocular surgery within the last two months or capsulotomy within the last month.
  4. History of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.
  5. Unstable fixation during microperimetry in either eye at either screening or baseline visits.

    Non-Ocular:

  6. Use of any other new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.
  7. Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.
  8. Liver or kidney disease, cystic fibrosis, asthma or (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.
  9. Suspected liver dysfunction determined by having (ALT), aspartate aminotransferase (AST), or values > 1.5 X the (ULN).
  10. or values that are below the lower limit of normal at screening (subjects with normal hemoglobin and mean corpuscular volume below the lower limit of normal should have iron studies performed to ensure that they are iron replete before taking part in the study), or neutrophils or white cell count which is above the upper limit of normal.
  11. Presence of more than + proteinuria on urinalysis at screening or (confirmed by abnormal albumin creatinine ratio).
  12. Presence of hematuria on urinalysis at screening. (If hematuria is detected on urinalysis, then the specimen should be subjected to microscopy, and subject should be excluded if more than 10 X 106 red blood cells/L.) If the subject is a female in whom the hematuria may be due to menses, then the urinalysis can be repeated after a few days.
  13. C-reactive protein (CRP) value above 10 mg/L.
  14. Subject has a recent history of presence of gross blood in stools.
  15. History of known sensitivity to N-acetylcysteine or similar thiol compounds.
  16. History of to any medication or food resulting in systemic symptoms.
  17. History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.
  18. Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.
  19. Lactating women who are breast-feeding.
  20. A potential participant lives in the same household as a current participant in this study.
  21. Inability to provide blood samples, including difficulty with venous access.
  22. Any reason, in the opinion of the Principal Investigator, the subject should not participate.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    NPI-001

    NPI-001 Tablet, 250 mg, BID

    Drug: NPI-001

  • Placebo comparator
    Placebo

    Placebo Tablet, BID

    Other: Placebo

Interventions

  • oral tablet

  • OtherPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo

    Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo

    Time frame: 24 months

07

Study locations

4 sites
  • Queensland Eye Institute
    Brisbane, Australia
  • CERA
    Melbourne, Australia
  • Lions Eye Institute
    Perth, Australia
  • Sydney Eye Hospital / Save Sight Institute
    Sydney, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jun 2025, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2020
First posted
Apr 21, 2020
StartActual
Sep 3, 2020
Primary completionActual
Jun 20, 2025
CompletionActual
Apr 22, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04355689
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Collaborators
Foundation Fighting Blindness, Nacuity Pharmaceuticals, PTY LTD
Responsible party
Sponsor
First posted
Apr 21, 2020
Start date
Sep 3, 2020
Primary completion
Jun 20, 2025
Completion
Apr 22, 2026
Last update
Jul 1, 2026

Study contacts

Lee Anderson, MD
study chair · Nacuity Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NPI-001

Start the discussion